Cargando…

Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial

BACKGROUND: Traumatic brain injury (TBI) is a significant contributor to global mortality and impairment. Experimental data has shown the advantages of remote ischemic preconditioning (RIPC) in treating brain injury, however, there is a lack of evidence-based medicine regarding its clinical effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Juan, Zhu, Lin, Shan, Yan, Wang, Yuhai, Liang, Changlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519565/
https://www.ncbi.nlm.nih.gov/pubmed/37746977
http://dx.doi.org/10.1097/MD.0000000000035190
_version_ 1785109728614940672
author Shen, Juan
Zhu, Lin
Shan, Yan
Wang, Yuhai
Liang, Changlei
author_facet Shen, Juan
Zhu, Lin
Shan, Yan
Wang, Yuhai
Liang, Changlei
author_sort Shen, Juan
collection PubMed
description BACKGROUND: Traumatic brain injury (TBI) is a significant contributor to global mortality and impairment. Experimental data has shown the advantages of remote ischemic preconditioning (RIPC) in treating brain injury, however, there is a lack of evidence-based medicine regarding its clinical effectiveness and safety. MATERIALS AND METHODS: In this study, we investigated whether RIPC could enhance outcomes in patients with severe TBI. Between January 2019 and December 2022, a comprehensive assessment was conducted on 392 individuals with severe TBI. Out of these, 304 patients were initially included and randomly assigned to receive either RIPC treatment (n = 153) or a control treatment (n = 151). The main measures of results included Glasgow Outcome Scale scores at 6 months, the occurrence of cerebral infarction during hospitalization, mortality rate within 30 days, levels of neuron-specific enolase and S-100β, any adverse effects, expenses incurred during hospitalization, and duration of hospital stay. RESULTS: The 2 groups did not show any statistically significant differences in baseline clinical data. The Glasgow Outcome Scale scores at 6 months in the RIPC group showed significant improvement when compared with the control group. Additionally, the application of RIPC therapy can reduce the concentrations of neuron-specific enolase and S-100β. There was no notable distinction observed between the 2 groups regarding the adverse reactions of RIPC-induced objective indications of tissue or neurovascular harm. In the RIPC group, there was a significant reduction in both the duration of hospital stays and the expenses associated with hospitalization. CONCLUSION: The results of this study suggest that RIPC has the potential to enhance clinical outcomes, mitigate nerve damage, and reduce both hospital expenses and length of stay in patients with severe TBI. The use of RIPC is a reliable and efficient method for managing severe TBI.
format Online
Article
Text
id pubmed-10519565
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105195652023-09-26 Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial Shen, Juan Zhu, Lin Shan, Yan Wang, Yuhai Liang, Changlei Medicine (Baltimore) 5300 BACKGROUND: Traumatic brain injury (TBI) is a significant contributor to global mortality and impairment. Experimental data has shown the advantages of remote ischemic preconditioning (RIPC) in treating brain injury, however, there is a lack of evidence-based medicine regarding its clinical effectiveness and safety. MATERIALS AND METHODS: In this study, we investigated whether RIPC could enhance outcomes in patients with severe TBI. Between January 2019 and December 2022, a comprehensive assessment was conducted on 392 individuals with severe TBI. Out of these, 304 patients were initially included and randomly assigned to receive either RIPC treatment (n = 153) or a control treatment (n = 151). The main measures of results included Glasgow Outcome Scale scores at 6 months, the occurrence of cerebral infarction during hospitalization, mortality rate within 30 days, levels of neuron-specific enolase and S-100β, any adverse effects, expenses incurred during hospitalization, and duration of hospital stay. RESULTS: The 2 groups did not show any statistically significant differences in baseline clinical data. The Glasgow Outcome Scale scores at 6 months in the RIPC group showed significant improvement when compared with the control group. Additionally, the application of RIPC therapy can reduce the concentrations of neuron-specific enolase and S-100β. There was no notable distinction observed between the 2 groups regarding the adverse reactions of RIPC-induced objective indications of tissue or neurovascular harm. In the RIPC group, there was a significant reduction in both the duration of hospital stays and the expenses associated with hospitalization. CONCLUSION: The results of this study suggest that RIPC has the potential to enhance clinical outcomes, mitigate nerve damage, and reduce both hospital expenses and length of stay in patients with severe TBI. The use of RIPC is a reliable and efficient method for managing severe TBI. Lippincott Williams & Wilkins 2023-09-22 /pmc/articles/PMC10519565/ /pubmed/37746977 http://dx.doi.org/10.1097/MD.0000000000035190 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5300
Shen, Juan
Zhu, Lin
Shan, Yan
Wang, Yuhai
Liang, Changlei
Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title_full Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title_fullStr Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title_full_unstemmed Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title_short Effects of remote ischemic preconditioning in severe traumatic brain injury: A single-center randomized controlled trial
title_sort effects of remote ischemic preconditioning in severe traumatic brain injury: a single-center randomized controlled trial
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519565/
https://www.ncbi.nlm.nih.gov/pubmed/37746977
http://dx.doi.org/10.1097/MD.0000000000035190
work_keys_str_mv AT shenjuan effectsofremoteischemicpreconditioninginseveretraumaticbraininjuryasinglecenterrandomizedcontrolledtrial
AT zhulin effectsofremoteischemicpreconditioninginseveretraumaticbraininjuryasinglecenterrandomizedcontrolledtrial
AT shanyan effectsofremoteischemicpreconditioninginseveretraumaticbraininjuryasinglecenterrandomizedcontrolledtrial
AT wangyuhai effectsofremoteischemicpreconditioninginseveretraumaticbraininjuryasinglecenterrandomizedcontrolledtrial
AT liangchanglei effectsofremoteischemicpreconditioninginseveretraumaticbraininjuryasinglecenterrandomizedcontrolledtrial